Clinical Trials Logo

Dermatomyositis, Adult Type clinical trials

View clinical trials related to Dermatomyositis, Adult Type.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06433999 Not yet recruiting - Dermatomyositis Clinical Trials

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, 12-week, open-label, single-arm study. The study population comprises individuals with refractory skin disease characteristic of dermatomyositis with no to minimal muscle involvement. After an up to 8-week Screening Period, eligible participants will receive brepocitinib 30 mg orally (PO) QD for 12 weeks.

NCT ID: NCT05986162 Not yet recruiting - Clinical trials for Dermatomyositis, Adult Type

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

Start date: December 30, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of Itolizumab in subjects with Dermatomyositis.